Cite
MLA Citation
P Rodríguez-Otero et al.. “P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY.” HemaSphere, vol. 6, n.d., pp. 22–23. http://access.bl.uk/ark:/81055/vdc_100153435583.0x00001d